Recombinant Human Histone H3.3 Protein: Use & Handling Guide

Recombinant Human Histone H3.3 Protein is a replication-independent histone variant critical for dynamic chromatin regulation, widely used in epigenetics and nucleosome reconstitution research.

Product Name

Recombinant Human Histone H3.3 Protein

SKU

rp366532

Protein Class

Histone variant (H3.3), replication-independent

Primary Applications

Nucleosome reconstitution, chromatin remodeling assays, epigenetic studies, in vitro binding assays

Source

Recombinant, expressed in a heterologous expression system

Storage Recommendation

Avoid repeated freeze-thaw cycles; store at -80 °C for long-term stability (verify with datasheet)

Overview of Histone H3.3 Biology

Histone H3.3 is a conserved replication-independent variant of histone H3 encoded in humans primarily by the H3F3A and H3F3B genes. Unlike the canonical replication-coupled histones H3.1 and H3.2, H3.3 is deposited into chromatin throughout the cell cycle, independent of DNA replication. This property makes it particularly enriched at actively transcribed genes, regulatory elements such as enhancers, and certain heterochromatic regions including telomeres.

H3.3 differs from H3.1 by five amino acid residues and from H3.2 by four residues, yet these subtle differences confer distinct chaperone interactions and genomic localization patterns. Key chaperone complexes involved in H3.3 deposition include HIRA (at euchromatic regions) and DAXX/ATRX (at telomeric and pericentromeric heterochromatin). The incorporation of H3.3 is tightly associated with active chromatin marks, including H3K4me3 and H3K36me3, contributing to epigenetic memory and transcriptional regulation.

Mutations in H3.3 (particularly K27M and G34R/V) have been identified as oncogenic drivers in pediatric high-grade gliomas, underscoring its importance in both normal development and disease. Recombinant Human Histone H3.3 Protein enables researchers to study these mechanisms in controlled biochemical and cell-free systems.

Protein Specifications and Quality Attributes

Recombinant Human Histone H3.3 Protein (SKU: rp366532) is manufactured to research-grade standards suitable for biochemical and cell-free applications. The following quality attributes are typical for recombinant histone preparations; researchers should consult the product-specific Certificate of Analysis (CoA) for lot-specific data:

• Expression system: Recombinant production in a heterologous host (verify expression host on current datasheet).
• Purity: High purity appropriate for nucleosome reconstitution and binding assays; specific purity percentage should be confirmed on the CoA.
• Form: Typically supplied as a lyophilized powder or liquid formulation; refer to current product datasheet for exact format and buffer composition.
• Molecular weight: Approximately 17 kDa for the core histone H3.3 polypeptide (may vary with tags or modifications; confirm on datasheet).
• Identity verification: Identity is typically confirmed by SDS-PAGE and/or mass spectrometry.

All lot-specific details including concentration, volume, and activity data are provided on the accompanying CoA. Contact Aladdin Scientific technical support for the most current specifications.

Reconstitution, Storage, and Handling

Proper handling of Recombinant Human Histone H3.3 Protein is essential to maintain its structural integrity and biological activity. The following guidelines represent best practices for recombinant histone proteins; always verify conditions against the product-specific datasheet supplied with each lot.

Reconstitution

• If supplied as a lyophilized powder, reconstitute in sterile, ultra-pure water or the buffer recommended on the product datasheet (e.g., 20 mM HEPES pH 7.5, 150 mM NaCl, or similar physiological buffer).
• Allow the vial to equilibrate to room temperature before opening to avoid moisture condensation on the protein.
• Gently pipette to mix; avoid vortexing, which can cause aggregation and denaturation.
• Prepare single-use aliquots immediately after reconstitution to minimize freeze-thaw cycles.

Storage

• For short-term use (up to 1 week), store at 4 °C.
• For long-term storage, aliquot and store at -80 °C. Avoid repeated freeze-thaw cycles, which progressively reduce protein activity and increase aggregation.
• Do not store at -20 °C in frost-free freezers, as temperature cycling can damage protein integrity.

General Handling Precautions

• Work on ice when setting up experiments requiring native protein activity.
• Use low-protein-binding tubes and pipette tips to minimize adsorptive losses, particularly at low protein concentrations.
• Centrifuge briefly at 4 °C before use to pellet any aggregates that may have formed during storage.

Recommended Applications

Recombinant Human Histone H3.3 Protein is a versatile reagent applicable across multiple areas of chromatin and epigenetics research:

• Nucleosome reconstitution: H3.3 can be combined with histones H2A, H2B, and H4 along with DNA of defined sequence to reconstitute nucleosomes in vitro via salt-dialysis or remodeling-factor-assisted methods. These reconstituted nucleosomes serve as substrates for enzymes including histone acetyltransferases, methyltransferases, and deacetylases.
• Chromatin remodeling assays: Use as a substrate to characterize the activity of ATP-dependent chromatin remodeling complexes such as SWI/SNF, ISWI, and CHD family members.
• Histone modification studies: Serve as a substrate for in vitro histone-modifying enzyme assays, enabling quantitative assessment of writing, erasing, and reading activities on H3.3-containing nucleosomes.
• Protein–protein interaction studies: Pull-down assays, co-immunoprecipitation controls, or surface plasmon resonance (SPR) experiments examining interactions between H3.3 and chaperones (e.g., HIRA, DAXX) or reader domains (e.g., bromodomains, chromodomains).
• Structural biology: Suitable as a component for cryo-EM or X-ray crystallography studies of nucleosome structure incorporating the H3.3 variant.
• Antibody validation: Use as a positive control antigen to validate anti-H3.3 antibody specificity in Western blot or dot blot formats.

Optimal working concentrations should be empirically determined for each specific assay format. Refer to relevant literature and the product datasheet for starting-point recommendations.

Quality Control and Troubleshooting

To obtain reproducible and reliable results with Recombinant Human Histone H3.3 Protein, the following quality control practices and troubleshooting strategies are recommended:

Quality Control Checks

• SDS-PAGE analysis: Run an aliquot on a 15–18% SDS-PAGE gel to confirm the expected molecular weight band and assess purity. A single predominant band is indicative of high-purity preparation.
• Protein quantification: Use a sensitive protein quantification method (e.g., BCA assay or absorbance at 280 nm using the calculated extinction coefficient) to confirm protein concentration matches the CoA.
• Activity verification: Where applicable, verify functional activity using an in vitro nucleosome reconstitution assay or histone-modifying enzyme assay prior to use in critical experiments.

Common Issues and Solutions

• Protein aggregation: If visible precipitation occurs, centrifuge at 10,000–16,000 × g for 10 min at 4 °C and use the supernatant. Aggregation often results from freeze-thaw cycling or improper reconstitution. Ensure reconstitution buffer is at the correct pH and ionic strength.
• Low activity in nucleosome reconstitution: Verify stoichiometry of all four histones; ensure high-purity DNA template; confirm salt-gradient dialysis conditions are optimized. H3.3 incorporation efficiency can be chaperone-dependent in more complex systems.
• Inconsistent results between lots: Always consult the CoA for lot-specific purity and concentration data. If significant variability is observed, contact Aladdin Scientific technical support with your CoA data and assay details.

Frequently asked questions

What is the difference between histone H3.3 and canonical H3.1 or H3.2?

Histone H3.3 is a replication-independent variant that is deposited into chromatin throughout the cell cycle, whereas H3.1 and H3.2 are incorporated primarily during DNA replication in S phase. H3.3 differs from H3.1 by five amino acid residues and is enriched at actively transcribed genes, enhancers, and certain heterochromatic regions such as telomeres. These differences result in distinct chaperone interactions and post-translational modification landscapes.

How should I reconstitute and store Recombinant Human Histone H3.3 Protein to preserve activity?

If supplied as a lyophilized powder, reconstitute the protein in sterile ultra-pure water or a physiological buffer as recommended on the product datasheet. Gently pipette to mix and avoid vortexing. Prepare single-use aliquots immediately after reconstitution and store long-term at -80 °C. Avoid repeated freeze-thaw cycles, as these progressively degrade protein activity and promote aggregation. Always verify storage and reconstitution conditions on the current product datasheet or CoA.

What applications is Recombinant Human Histone H3.3 Protein suitable for?

This protein is suitable for in vitro nucleosome reconstitution, chromatin remodeling assays, histone modification enzyme assays, protein–protein interaction studies (e.g., with chaperones such as HIRA and DAXX or epigenetic reader domains), structural biology studies, and antibody validation. Optimal working concentrations should be determined empirically for each assay format.

Why are H3.3 mutations clinically significant?

Specific point mutations in H3.3, most notably K27M and G34R/V, have been identified as oncogenic drivers in pediatric high-grade gliomas including diffuse intrinsic pontine glioma (DIPG). These mutations disrupt normal epigenetic regulation by altering histone methylation patterns, leading to widespread chromatin dysregulation. Recombinant H3.3 proteins bearing such mutations are used in research to dissect these pathogenic mechanisms in biochemical systems.

References

1. Maze I, Noh KM, Allis CD. Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology. 2013;38(1):3-22.
2. Goldberg AD, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140(5):678-691.
3. Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-231.
4. Drane P, Ouararhni K, Depaux A, Shuaib M, Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010;24(12):1253-1265.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.